Researchers Are Creating New Vaccine to Target Opioid Addiction
Virus-like particle research could lead to a vaccine against opioid addiction.
FDA Approves Kanjinti for HER2 Cancers
Indications include breast cancer, metastatic gastric cancer, and metastatic gastroesophageal junction adenocarcinoma.
New Drug Review: Spravato
Both responder and remitter patients experienced a statistically significant longer time to relapse with esketamine compared to the placebo
On the Road to Provider Status
Billing solutions and entrepreneurs needed.
Pharmacy Organizations Issue Letter on DIR Fees
DIR abuse might require Presidential and Congressional intervention.
Five Tips for Evaluating Clinical Studies
Be an expert at evaluating clinical studies with some simple tools.
FDA Approves Polivy for Large B-Cell Lymphoma
Drug targets the CD79b protein on B-cells.
Maintain Control of Controlled Substances
Comply with state and federal regulations on dispensing and handling controls to avoid possible disciplinary or DEA actions and penalties.
NACDS Pushes for Naloxone, National PDMP
Organization calls for state-level legislative and regulatory revisions.
Opinion: Training the Technicians
Figuring out the equations for quality technicians.
Mass. HPC: Transparency for PBM Spread Pricing
Results from a new Massachusetts Health Policy Commission report.
Herpes Zoster and IBD: What Are the Risks?
Two studies outline the risks of shingles for patients with IBD.
Shingles in Space!
A study finds herpes viruses can reemerge under the stresses of spaceflight.
New Emergency Medicine Certificate from ASHP
Pharmacists can earn up to 27 hours of CE.
CVS Will Offer HealthHUBs at 1,500 Stores
CVS will expand its health offerings, including nutrition and weight loss.
Hospital Drug Diversion: An Underreported Threat
Results of a recent survey suggest employee-based drug abuse is a concern for many healthcare providers, though they don’t believe it can happen in their facilities.
FDA Approves Zerbaxa for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
Zerbaxa is a cephalosporin antibacterial and beta-lactamase inhibitor combination drug originally approved for abdominal and urinary tract infections.
FDA Approves First Drug to Treat Episodic Cluster Headaches in Adults
Patients on Emgality experienced an average of 8.7 fewer weekly episodic cluster headaches.
Training Technicians for More Responsibility
Training programs reflect the changing practice of pharmacies.
Maximizing Medication Therapy Management Services
Improve your counseling skills to make the most of medication therapy management in your community pharmacy.
COTA Signs Agreement with FDA for Breast Cancer Research
The agreement will bring real-world data to cancer treatment development.
Compounding Pharmacy Ordered to Cease Operations
After several manufacturing and sterility issues, a permanent injunction has been issued against a Pharm D Solutions, LLC.
Morris & Dickson Settle for $22 Million for Failing to Report Suspicious Opioid Orders
The action by the U.S. Attorney's Office is the latest in legal and policy maneuvers aimed at ending the opioid epidemic.
ASHP and ASPEN Launch Professional Nutritional Support Certificate
Earn up to 19.25 hours of CE.
Lenalidomide Approved by FDA for Follicular and Marginal Zone Lymphoma
This thalidomide analogue is also indicated for multiple myeloma and myelodysplastic syndromes.
FDA Approves Vraylar (Cariprazine) for Bipolar Depression
New indication adds to the oral antipsychotic’s portfolio of conditions.
FDA Approves PI3K Inhibitors for Breast Cancer
First PIK3CA inhibitor treatment approved, along with diagnostic test.
New Gene Therapy for Pediatric Spinal Muscular Atrophy Approved by FDA
Zolgensma (onasemnogene abeparvovec-xioi) is an adeno-associated virus vector-based gene therapy
DOAC Use Increasing in Nursing Homes
The use of direct‐acting oral anticoagulants has increased among nursing home residents with atrial fibrillation.
Atrial Fibrillation Patients Often Overestimate Stroke and Bleeding Risks
Overestimating the bleeding risk of anticoagulants may lead to poor compliance.
